AKT1 is an inclusion eligibility criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR is an inclusion eligibility criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Dasatinib, imatinib, sorafenib, and sunitinib have evidence of efficacy in patients with KIT mutation in thymic carcinoma [3].

KRAS is an inclusion eligibility criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK1 is an inclusion eligibility criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NTRK1 status and thymic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PTEN is an inclusion eligibility criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].